Nucleome Therapeutics

Nucleome was founded in 2019. The precision of its 3D genomics technology has the potential to improve drug discovery success rates both by discovering genetically validated medicines, and by more accurately identifying patients who are likely to benefit from particular treatments. Nucleome’s platform can be applied to multiple disease indications and cell types, with an initial focus on inflammatory conditions.